Dopamine activation of endogenous cannabinoid signaling in dorsal striatum

A. Giuffrida, L. H. Parsons, T. M. Kerr, F. Rodríguez de Fonseca, M. Navarro and D. Piomelli

1 Department of Pharmacology, 360 M ed Surge II, University of California at Irvine, Irvine, California 92697-4625, USA
2 Department of Neuropharmacology, The Scripps Research Institute, La Jolla, California 92037, USA
3 Department of Psychobiology, Universidad Complutense, Madrid, 28233, Spain

We measured endogenous cannabinoid release in dorsal striatum of freely moving rats by microdialysis and gas chromatography/mass spectrometry. Neural activity stimulated the release of anandamide, but not of other endogenous cannabinoids such as 2-arachidonylglycerol. Moreover, anandamide release was increased eightfold over baseline after local administration of the D2-like (D2, D3, D4) dopamine receptor agonist quinpirole, a response that was prevented by the D2-like receptor antagonist raclopride. Administration of the D1-like (D1, D5) receptor agonist SKF38393 had no such effect. These results suggest that functional interactions between endocannabinoid and dopaminergic systems may contribute to striatal signaling. In agreement with this hypothesis, pretreatment with the cannabinoid antagonist SR141716A enhanced the stimulation of motor behavior elicited by systemic administration of quinpirole. The endocannabinoid system therefore may act as an inhibitory feedback mechanism counteracting dopamine-induced facilitation of motor activity.

RESULTS
Anandamide release in vivo
We examined the occurrence and regulation of endogenous cannabinoid release in the dorsal striatum of freely moving rats by using microdialysis combined with isotope dilution gas chromatography/mass spectrometry (GC/MS). Microdialysis samples obtained during 30-min collections under baseline conditions contained detectable levels of anandamide (1.5 ± 0.3 pmol per sample, mean ± s.e.m., n = 60; Fig. 1), palmitylethanolamide (PEA), an acylethanolamide that activates peripheral CB2-like receptors, and oleylethanolamide, the functions of which remain unknown. Anandamide was not detectable under these conditions (data not shown). No measure was taken in these analyses to prevent the uptake and enzymatic hydrolysis of anandamide and 2-AG; thus the impact of these inactivation processes on endogenous cannabinoid levels remains to be determined.

The striatum is a key component of the forebrain system that controls planning and execution of motor behaviors. Excitatory signals generated in sensorimotor and limbic areas of the neocortex and in the thalamus converge on this region, where they are integrated and redistributed to other structures of the basal ganglia and to the substantia nigra. How the striatum integrates these inputs, which are mediated by the fast neurotransmitter glutamate, is only partially understood. Nevertheless, it is generally agreed that slow-acting modulatory substances, including dopamine, acetylcholine and neuroactive peptides, participate in this process by influencing the excitability of striatal neurons. In support of this idea, abnormalities in striatal neuromodulation have been linked to a spectrum of neuropsychiatric disorders, of which Parkinson's disease and Tourette's syndrome are two well-documented examples.

Cannabinoid receptors, the pharmacological target of the marijuana constituent tetrahydrocannabinol, are densely expressed in striatum, where they are twice as numerous as D1 dopamine receptors and 12 times as numerous as mu opioid receptors. Activation of cannabinoid receptors has profound consequences on the electrophysiological properties of striatal neurons, as well as on motor behaviors that are mediated by striatal projection systems. Furthermore, clinical observations suggest that marijuana and 9-THC may be beneficial in several neuropsychiatric disorders associated with the basal ganglia, such as Parkinson's disease and Tourette's syndrome, pointing to an involvement of cannabinoid receptors in abnormal striatal function. Interpreting these results is made difficult, however, by our inadequate knowledge of the intrinsic signaling system by which cannabinoid receptors are engaged. Indeed, although several endogenous cannabinoid (endocannabinoid) ligands, including anandamide and 2-arachidonylglycerol, have been identified and their biosynthetic routes partially elucidated, the physiological mechanisms that regulate release of these compounds remain elusive.

To test whether endogenous cannabinoids are released by neural activity, we perfused the striatum with artificial cerebrospinal fluid (ACSF) containing a depolarizing concentration...
of KCl (60 mM). This high-K⁺ pulse significantly increased anan-
damide outflow (Fig. 2a), whereas it had no effect on PEA,
oleylethanolamide or 2-AG (Fig. 2c and data not shown; n = 13).
After reinstatement of normal ACSF, anandamide levels rapidly
returned to basal values (Fig. 2a). The overall time course of this
response was identical to that of K⁺-induced dopamine release,
measured in parallel microdialysate samples (Fig. 2b). The effect
of high K⁺ on anandamide outflow was prevented either by the
Na⁺-channel blocker tetrodotoxin (1 μM) or by removal of Ca²⁺
ions, two treatments that alone had no significant effect on basal
anandamide levels (Fig. 3). These results demonstrate that anan-
damide is released in the dorsal striatum of freely moving rats
during neural activity, fulfilling an essential criterion for this lipid
to be considered a neuromodulator in the central nervous sys-
tem (CNS). Furthermore, the finding that 2-AG and PEA may
not be released during neural activity indicates that in striatum
such a role is specific to anandamide.

D₂ receptors stimulate anandamide release

The modulatory neurotransmitter dopamine regulates essential
aspects of striatal physiology by interacting with two pharma-
cologically distinct groups of G-protein-coupled receptors, D₁-
like (D₁ and D₅) and D₂-like (D₂, D₃ and D₄)³¹,³². To determine
whether activation of dopamine receptors in striatum affects
anandamide release, we locally applied by reverse dialysis selective
D₂-like agonist quinpirole resulted in an eightfold stimulation of
anandamide outflow (Fig. 4a). Extracellular anandamide levels
remained elevated for at least two hours after quinpirole admin-
istration (Fig. 4a), possibly as a result of slow clearance of the
drug from its site of application. In support of this possibility,
when the D₂-like antagonist raclopride (20 μM) was adminis-
tered after quinpirole, baseline anandamide levels were reached
within 30–60 min (data not shown). As with high K⁺, the out-
puts of 2-AG, PEA and oleylethanolamide were not affected by
quinpirole (data not shown).

To investigate the receptor mechanism underlying the
response to quinpirole, we examined the effects of the D₂-like
agonist raclopride. Raclopride (20 μM) did not affect micro-
dialysate anandamide concentrations when applied alone, but
completely prevented the stimulatory effects of quinpirole
(Fig. 4b).
did not change the basal outflows of anandamide (Fig. 4c). PEA, 2-AG or oleylethanolamide (data not shown). The lack of effect of SKF38393 underscores the differences between D2-like and D2-like receptor agonists with respect to anandamide release, but does not rule out the possibility that D2-like receptors may regulate this process in other ways, for example by acting synergistically or antagonistically with D2-like receptors.

Modulation of motor activity

The results of these neurochemical experiments indicate that dopamine acting at D2-like receptors stimulates anandamide release in dorsal striatum, suggesting that the endocannabinoid system participates in dopaminergic regulation of striatal function. To test this possibility, we determined whether the behavioral response elicited by systemic administration of quinpirole in rats is affected by the CB1 receptor antagonist SR141716A33. In agreement with previous results34, quinpirole (1 mg per kg) caused a biphasic motor response characterized by transient suppression of movement, which is thought to be caused by activation of presynaptic D2-like receptors, followed by a longer-lasting hyperactivity, possibly due to activation of postsynaptic D2-like receptors34,35. This response included changes in horizontal locomotion, time spent in immobility and sniffing frequency (Fig. 5). As previously reported36, SR141716A had no overt effect on motor activity when given alone at a dose of 1 mg per kg (Fig. 5). Nevertheless, when SR141716A was injected at the same dose 60 min before quinpirole, the late phase of quinpirole-induced motor activation was markedly potentiated, whereas the initial phase of motor suppression remained unchanged (Fig. 5). Thus pharmacological blockade of CB1 receptors enhances the motor stimulation produced by activation of postsynaptic D2-like receptors, but has little or no effect either on basal motor activity or on presynaptic D2-receptor-dependent motor inhibition.

DISCUSSION

In striatal and cortical neurons in primary culture, formation of anandamide is stimulated by membrane depolarization, suggesting that this compound may be produced during neural activity and participate in endocannabinoid signaling15,18. Here we used a combination of microdialysis and GC/MS techniques26 to investigate the release of anandamide and other endogenous cannabinoid substances in the dorsal striatum of freely moving rats. We found that neural activity evoked by a localized pulse of high K+ stimulates the outflow of anandamide, but not 2-AG and PEA. The possibility implied by these findings that anandamide acts as a neural mediator in striatum is supported by both anatomical and pharmacological evidence. GABAergic medium spiny neurons, which account for about 95% of the striatal neuron population and are the source of most striatofugal projections27, contain large numbers of CB1 cannabinoid receptors8. Activation of these receptors causes presynaptic inhibition of GABA release, which affects motor behaviors in vivo37,38. Indeed, certain aspects of the motor inhibition produced by systemically administered cannabimimetic drugs, such as attenuation of stereotyped behaviors, may be mediated by their ability to activate striatal CB1 receptors99. By showing that anandamide is released in striatum during neural activity, our results point to this endogenous cannabinoid lipid as a primary component of the network of neurally active substances that regulate striatal function2.

Brain tissue contains 2-AG in amounts 170 times greater than anandamide18,40. Thus, we were surprised to find that the extracellular levels of this compound in striatum are undetectable both under baseline conditions and during neural activity. Limitations of our isotope dilution assay are unlikely to account for this negative result, as this method provides very similar detection limits for 2-AG (1 pmol per sample) and anandamide (0.4 pmol per sample, see Methods). Differences in biological inactivation are also an improbable explanation, because 2-AG and anandamide are eliminated at comparable rates (M. Beltramo and D.
whose genes have been isolated thus far. Pharmacological experiments indicate, however, that, in peripheral tissues, PEA activates a CB2-like receptor, which mediates antinociception and anti-inflammation. Unlike neurotransmitters and neuropeptides, which are released from synaptic terminals via vesicle secretion, anandamide may be produced and released upon demand by a mechanism that involves phospholipase-mediated cleavage of the membrane phospholipid precursor N-arachidonylphosphatidylethanolamine. Such a nonvesicular release process suggests that anandamide may act in the CNS more as an autacoid (local mediator) substance than as a classical neuromodulator. Lipid autacoids such as the eicosanoids and platelet-activating factor are formed by receptor-mediated cleavage of phospholipids and act near their sites of production, where they are also rapidly inactivated.

That anandamide may conform to this model is suggested by our finding that occupation of striatal D2-like dopamine receptors dramatically stimulates anandamide outflow. A parsimonious interpretation of this result is that anandamide may be released from striatal neurons or nigrostriatal dopaminergic terminals, both of which bear D2-like receptors, and may exert its effects within a confined volume of striatal tissue.

What, if any, is the physiological function of striatal anandamide release? We have begun to address this question by studying the effects of the selective CB1 receptor antagonist SR141716A on the behavioral responses produced by quinpirole in rats. The results show that, although SR141716A has no overt effect when administered alone, it enhances the motor activation elicited by quinpirole. The inverse agonist properties of SR141716A, which have been characterized in vitro, cannot account for such a differential effect; a more plausible interpretation that is also consistent with our neurochemical data is that pharmacological blockade of cannabinoid receptors increases quinpirole-induced hyperactivity by removing the inhibitory control of endogenously released anandamide. According to this hypothesis, occupation of D2-like receptor by dopamine elicits the release of anandamide in striatum and possibly in other regions of the CNS that contribute to movement control. By engaging CB1 receptors, anandamide may act in turn to counter dopamine stimulation of motor activity, which is thought to be mediated by postsynaptic D2-like and D1-like receptors. In further support of this hypothesis, anandamide inhibits movement when it is administered as a drug, and cannabimimetic agents attenuate amphetamine-evoked hyperactivity. The functional interaction between anandamide and dopamine demonstrated in this study suggests a possible participation of the endogenous cannabinoid system in pathologies that involve dysregulation of dopamine neurotransmission. Thus, our findings may have implications for neuropsychiatric disorders such as schizophrenia, Tourette’s syndrome and Parkinson’s disease and may point to novel therapeutic approaches for these conditions.

**Methods**

**Drugs.** SR141716A (N-[(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide•HCl) was provided by RBI (Natick, Massachusetts) as part of the Chemical Synthesis Program of the NIMH (N01MH30003); all other drugs were from RBI or Sigma (St. Louis, Missouri).

**Microdialysis.** Male Wistar rats (Charles River, Holister, California) were anesthetized with halothane (1.0–1.5%), and stainless steel microdialysis guide cannulae (model CM A/10; Carnegie Medicine Apparatus, Solna, Sweden) were implanted in the caudate-putamen (from Bregma A +1.0 mm, L + 2.5 mm; from dura V – 2.8 mm). A recovery period of at least 5 days was allowed before the experiments. Approximately 12 hours before
the microdialysis sessions, animals were lightly anesthetized (1-2% halothane), and microdialysis probes (model CMA/10, Carnegie Medicine Apparatus; 4 mm active length) were inserted into the guide cannulae. Anesthesia was sufficiently brief so that animals regained movement within 3 min of probe insertion. An artificial cerebrospinal fluid (ACSF) consisting of 145 mM NaCl, 2.8 mM KCl, 1.2 mM CaCl$_2$, 1.2 mM MgCl$_2$, 0.25 mM ascorbic acid and 5.4 mM D-glucose (pH 7.2–7.4) was used as perfusion medium; this solution was delivered at a flow rate of 0.2 µl per min until two hours before the start of the experiment when the flow rate was increased to 10 µl per min. Preliminary experiments indicated that this relatively high flow rate was necessary to collect a sufficient amount of endogenous cannabinoids for reliable detection under baseline conditions. In vitro recovery of [3H]anandamide was 58 ± 0.2% (n = 3), which was comparable to that of dopamine under similar flow-rate conditions. Dialysate concentrations were not corrected for recovery. Probe outlet tubing was modified to reduce back-pressure so that no ultrafiltration was observable across the dialysis membrane. The ACSF was delivered to the probes via a single-channel liquid swivel (Instech, Plymouth Meeting, Pennsylvania) attached to a balance arm above the animal cage to ensure freedom of movement during the experiment. Microdialysis samples were collected at 30-min intervals into glass vials containing internal standards for GC/MS analysis (1.2 nmol of each [3H]jyclylcholamidine and 1.0 nmol of [3H]2-AG) in 1 ml methanol. At the end of each experiment, microdialysis probe placement was verified histologically.

**Analytical procedures.** Microdialysis samples were extracted with chloroform/methanol, fractionated by high-performance liquid chromatography (HPLC) and analyzed by GC/MS as described. N. Stella and D. Piomelli, unpublished results. [3H]Jyclylcholamidines were prepared following standard procedures and [3H]2-AG was purchased from Deva Biotech (Hartboro, Pennsylvania). The limit of detection, that is, the injected quantity that produced a signal corresponding to an average blank plus 3 standard deviations, was 0.4 pmol for anandamide, 0.1 pmol for PEA, 0.1 pmol for oleylethanolamide and 1 pmol for 2-AG (N. Stella and D. Piomelli, unpublished data). Concentrations in microdialysis perfusates are expressed as percent of baseline values, which were calculated by averaging the first three samples collected before treatment. Dopamine was measured by HPLC and electrochemical detection (N. Stella and D. Piomelli, unpublished results). [2H4]acylenolamides were prepared by enzymatic synthesis of anandamide, an endogenous cannabinoid precursor, using anandamide amidohydrolase (N. Stella and M. J. Walker for comments and discussion. Part of this work was conducted at the Neurosciences Institute and was supported by Neurosciences Research Foundation, which receives major support from Novartis. Additional support was from the National Institute of Drug Abuse (DA12447 and DA12413, to D.P.), CICYT and Plan Nacional sobre Drogas (F.R.F., M.N.). F.R.F. is a research fellow of the Jaume I Rector Foundation.

**Received 22 October 1998; accepted 13 January 1999**

1. Gerfen, C. R. The neostriatal mosaic: multiple levels of compartmental organization. Annu. Rev. Neurosci. 15, 285–320 (1992).
2. Graybiel, A. M., Aosaki, T., Flaherty, A. W. & Kimura, M. The basal ganglia and adaptive motor control. Trends Neurosci. 15, 1205–1233 (1992).
3. Chase, T. N., Engber, T. M. & Mouradian, M. M. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. Adv. Neurol. 69, 497–501 (1996).
4. Wolf, S. S. et al. Tourette syndrome prediction of phenotypic variation in monozygotic twins by caudate nucleus D2 receptor binding. Science 273, 1225–1227 (1996).
5. Eidelberg, D. et al. The metabolic anatomy of Tourette's syndrome. Neurology 48, 927–934 (1997).
6. Herkenham, M. et al. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. USA 87, 1932–1936 (1990).
7. Matsuda, L. A., Loliat, S. J., Brownstein, M., Young, A. & Bonner, T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561–564 (1990).
8. Herkenham, M. et al. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11, 563–583 (1991).
9. Sim, L. J., Sfety, D. E., Xiao, R. & Childers, S. R. Differences in G-protein activation by µ- and δ-opioid, and cannabinoid receptors in rat striatum. Eur. J. Pharmacol. 307, 97–106 (1996).
10. Szabo, B., Dörner, L., Pfreundtner, C., Nörenberg, W. & Starke, K. Inhibition of GABAergic inhibitory postynaptic currents by cannabinoids in rat corpus striatum. Neuroscience 85, 395–403 (1998).
11. Sañudo-Peña, M. C., Patrick, S. L., Patrick, R. L. & Walker, J. M. Effects of intraganglionic cannabinoids on rotational behavior in rats; interactions with the dopaminergic system. Neurosci. Lett. 206, 21–24 (1996).
12. Hemming, M. & Yellowlees, P. M. Effective treatment of Tourette's syndrome with marijuana. J. Psychopharmacol. 7, 389–391 (1993).
13. Miller-Vahl, K. R., Schneider, U., Kolbe, H. & Emrich, H. M. Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol. Am. J. Psychiatry (in press).
14. Devane, W. et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946–1949 (1992).
15. Di Marzo, V. et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372, 689–691 (1994).
16. Sugiura, T. et al. 2-Arachidonylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215, 89–95 (1995).
17. Machoulam, R. et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50, 83–90 (1995).
18. Stella, N., Schwetzler, F. & Piomelli, D. A second endogenous cannabinoid receptor blocks L-NAME-induced long-term potentiation. Nature 389, 73–77 (1997).
19. Cadas, H., di T omaso, E. & Piomelli, D. Occurrence and biosynthesis of anandamide, an endogenous cannabinoid precursor, in rat brain. J. Neurosci. 17, 1226–1242 (1997).
20. Sugiura, T. et al. Transacylase-mediated conversion and regulation of anandamide, an endogenous cannabinoid in rat brain. J. Neurosci. 17, 1226–1242 (1997).
21. Sugiura, T. et al. Enzymatic synthesis of anandamide, an endogenous cannabinoid receptor ligand, through N-acylethanolamidase-mediated synthesis of N-arachidonylethanolamine, an endogenous cannabinoid receptor ligand, in rat brain microsomes. Eur. J. Biochem. 240, 53–62 (1996).
22. Sugiura, T. et al. Enzymatic synthesis of anandamide, an endogenous cannabinoid receptor ligand, through N-acylethanolamidase-mediated synthesis of N-arachidonylethanolamine, an endogenous cannabinoid receptor ligand, in rat brain microsomes. Eur. J. Biochem. 240, 53–62 (1996).
23. Giuffrida, A. & Piomelli, D. Isotope dilution GC/MS determination of anandamide and other fatty acylethanolamides in rat blood plasma. FEBS Lett. 422, 373–376 (1998).
24. Facci, L. et al. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. USA 92, 3367–3370 (1995).
25. Calignano, A., La Rana, G., Giuffrida, A. & Piomelli, D. Control of pain by endogenous cannabinoids. Nature 394, 277–281 (1998).
26. Schmid, H. H. O., Schmid, P. C. & Natarajan, V. The N-acyltyramine-phosphodiesterase pathway and cell signalling. Chem. Phys. Lipids 80, 133–142 (1996).
27. Desarnaud, F., Cadas, H. & Piomelli, D. Anandamide amidohydrolase activity in rat brain microsomes: identification and partial characterization. J. Biol. Chem. 270, 6030–6035 (1995).
28. Ueda, N., Kurahashi, Y., Yamamoto, S. & Tokunaga, T. Partial purification and characterization of the porcine brain enzyme hydrolyzing and synthesizing anandamide. J. Biol. Chem. 270, 23823–23827 (1995).
29. Hillard, C. J., Wilkison, D. M., Edgemont, W. S. & Campbell, W. B. Characterization of the kinetics and distribution of N-arachidonylethanolamine (anandamide) hydrolysis by rat brain. Biochim. Biophys. Acta 1257, 249–256 (1995).
29. Cravatt, B. F. et al. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature \textbf{384}, 83–87 (1996).
30. Beltramo, M. et al. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science \textbf{277}, 1094–1097 (1997).
31. Civelli, D. in Psychopharmacology: The Fourth Generation of Progress (eds. Bloom, F. E. & Kupfer, D. J.) 155–161 (Raven, New York, 1995).
32. Surmeier, D. J., Yan, Z. & Song, W. J. Coordinated expression of dopamine receptors in neostriatal medium spin neurons. Adv. Pharmacol. \textbf{42}, 1020–1023 (1998).
33. Rinaldi-Carmona, M. et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. \textbf{350}, 240–244 (1994).
34. Eilam, D. & Szechtman, H. Biphasic effect of D-2 agonist quinpirole on locomotion and movements. Eur. J. Pharmacol. \textbf{161}, 151–157 (1989).
35. Thorn, L., Ashe, S. E., Storey, V. J., Routledge, C. & Ross, G. C. Evidence to suggest that agonist modulation of hyperlocomotion is via post-synaptic dopamine D2 or D3 receptors. Neuropharmacology \textbf{36}, 767–792 (1997).
36. Compton, D. R., Aceto, M. D., Lowe, J. & Martin, B. R. In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of \(\Delta^{9}\)-tetrahydrocannabinol-induced responses and apparent agonist activity. J. Pharmacol. Exp. Ther. \textbf{277}, 586–594 (1996).
37. Gough, A. L. & Olley, J. E. Catalepsy induced by intrastriatal injections of \(\Delta^{9}\)-THC and 11-OH-\(\Delta^{9}\)-THC in the rat. Neuropharmacology \textbf{36}, 137–144 (1997).
38. Souilhac, J., Pineau, C., Rinaldi-Carmona, M., Le Fur, G. & Soubrié, P. Intrastratal injection of cannabinoid receptor agonist induced turning behavior in mice. Pharmacol. Biochem. Behav. \textbf{51}, 3–7 (1995).
39. Navarro, M. et al. Motor disturbances induced by an acute dose of \(\Delta^{9}\)-tetrahydrocannabinol: possible involvement of nigrostriatal dopaminergic alterations. Pharmacol. Biochem. Behav. \textbf{45}, 291–298 (1993).
40. Kondo, S. et al. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor agonist: identification as one of the major species of monoacylglycerols in various rat tissues, and evidence for its generation through \(\Delta^{9}\)-dependent and independent mechanisms. FEBS Lett. \textbf{429}, 152–156 (1998).
41. Showalter, V. M., Compton, D. R., Martin, B. R. & Abood, M. E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. \textbf{278}, 989–999 (1996).
42. Matsuda, L. A. Molecular aspects of cannabinoid receptors. Crit. Rev. Neurobiol. \textbf{11}, 143–166 (1997).
43. Cadas, H., Gaillet, S., Beltramo, M., Venance, L. & Piomelli, D. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J. Neurosci. \textbf{16}, 3934–3942 (1996).
44. Piomelli, D. in Psychopharmacology: The Fourth Generation of Progress (eds. Bloom, F. E. & Kupfer, D. J.) 595–607 (Raven, New York, 1995).
45. Landsman, R. S., Burkey, T. H., Comroe, P., Roeske, W. R. & Yamamura, H. I. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur. J. Pharmacol. \textbf{334}, R1–2 (1997).
46. Waddington, J. L., Molloy, A. G., O’Boyle, K. M. & Pugh, M. T. in Neurobiology of Stereotyped Behaviour (eds. Cooper, S. J. & Dourish, C. T.) 64–90 (Clarendon, Oxford, 1990).
47. Fride, E. & Mechoulam, R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur. J. Pharmacol. \textbf{231}, 313–314 (1993).
48. Pryer, G. T., Larsen, F. F., Husain, S. & Braude, M. C. Interactions of \(\Delta^{9}\)-tetrahydrocannabinol with \(d\)-amphetamine, cocaine, and nicotine in rats. Pharmacol. Biochem. Behav. \textbf{8}, 295–318 (1978).
49. Parsons, L. H. & Justice, J. B. J. Quantitative approaches to in vivo brain microdialysis. Crit. Rev. Neurobiol. \textbf{8}, 189–220 (1994).
50. Parsons, L. H. et al. Neurochemical evidence that postsynaptic nucleus accumbens D3 receptor stimulation enhances cocaine reinforcement. J. Neurochem. \textbf{67}, 1078–1089 (1996).